{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:12:28Z","timestamp":1776435148410,"version":"3.51.2"},"reference-count":23,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>As patients with relapsed\/refractory multiple myeloma (RRMM) continue to live longer, they might get exposed to most available drugs and drug classes during the disease course. For such late line RRMM or among patients without access to novel therapies, retreatment with a drug that the disease had previously been refractory to might be one option. In this retrospective study, we describe 315 patients with RRMM at our institution who were retreated with a drug that the disease had been previously refractory to. We found an overall response rate of 56.2% and a median progression-free survival (PFS) of 11\u00a0months with retreatment. Patients with a longer time on initial therapy with the index drug (&amp;gt;28.4\u00a0months) had a superior PFS with retreatment (median PFS, 16.9 vs 8.1\u00a0months; P\u00a0&amp;lt;\u00a0.001). Similarly, patients with a longer time gap between the initial line of therapy with index drug and retreatment with index drug (&amp;gt;46.1\u00a0months) had better PFS with retreatment (28.2 vs 8.9\u00a0months; P\u00a0=\u00a0.016). In conclusion, retreatment with a previously refractory drug is a viable therapeutic option for RRMM, with the most significant benefit derived in disease demonstrating sensitivity to initial drug exposure and among those with a longer gap between initial drug exposure and retreatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014723","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T21:02:52Z","timestamp":1731531772000},"page":"6321-6328","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Retreatment of multiple myeloma with previously refractory drugs"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-0325","authenticated-orcid":false,"given":"Utkarsh","family":"Goel","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"},{"name":"2Department of Internal Medicine, Cleveland Clinic, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalampos","family":"Charalampous","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9488-8212","authenticated-orcid":false,"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam A.","family":"Hobbs","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi L.","family":"Hwa","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-1559","authenticated-orcid":false,"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0326","authenticated-orcid":false,"given":"Rahma M.","family":"Warsame","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"issue":"5","key":"2024122319551935400_bib1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2024122319551935400_bib2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"2024122319551935400_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"2024122319551935400_bib4","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"17","key":"2024122319551935400_bib5","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1002\/cncr.32177","article-title":"Recycling therapies for myeloma: the need for prospective trials","volume":"125","author":"Kumar","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"2024122319551935400_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00277-018-3524-1","article-title":"Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)","volume":"98","author":"Musto","year":"2019","journal-title":"Ann Hematol"},{"issue":"1","key":"2024122319551935400_bib7","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1002\/hsr2.104","article-title":"Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice","volume":"2","author":"Hulin","year":"2019","journal-title":"Health Sci Rep"},{"issue":"9","key":"2024122319551935400_bib8","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"issue":"21","key":"2024122319551935400_bib9","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","article-title":"CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies","volume":"7","author":"Perez de Acha","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2024122319551935400_bib10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.clml.2023.07.007","article-title":"Clinical efficacy of retreatment with venetoclax-based therapy in relapsed-refractory t(11;14) multiple myeloma","volume":"23","author":"Dima","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2024122319551935400_bib11","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ejh.13942","article-title":"Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma","volume":"110","author":"Abdallah","year":"2023","journal-title":"Eur J Haematol"},{"issue":"3","key":"2024122319551935400_bib12","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1111\/bjh.17393","article-title":"Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy","volume":"193","author":"Kunacheewa","year":"2021","journal-title":"Br J Haematol"},{"issue":"17","key":"2024122319551935400_bib13","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/cncr.32178","article-title":"Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"2024122319551935400_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"18","key":"2024122319551935400_bib15","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"15","key":"2024122319551935400_bib16","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2024122319551935400_bib17","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024122319551935400_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"2024122319551935400_bib19","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2024122319551935400_bib20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2024122319551935400_bib21","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"7339","key":"2024122319551935400_bib22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"5","key":"2024122319551935400_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.12198","article-title":"A\u00a0prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma","volume":"160","author":"Petrucci","year":"2013","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/24\/6321\/2347158\/blooda_adv-2024-014723-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/24\/6321\/2347158\/blooda_adv-2024-014723-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T19:55:31Z","timestamp":1734983731000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/24\/6321\/525979\/Retreatment-of-multiple-myeloma-with-previously"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":23,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,12,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014723","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]}}}